Trial Information

Storing Blood for Analysis of DNA and Protein of Patients With Endometrial Carcinoma in MAASTRO Clinic

It has already been known for a long time that cancer is a genetic disorder and that the
development of the illness is a very complex interaction between genetic and surrounding
factors. Also the response on therapy and the development and seriousness of side effects is
stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it
is not only the DNA that plays an important role but also the systems of control at protein
level. At this moment a lot of questions remain to be answered because up till now the
studies were of rather restricted statistical strength with frequently inconsistent dates
and moreover retrospective. Major retrospective studies are necessary to distinguish the
relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and
toxicity in which an as broad as possible patient group is being monitored. For this reason
we want to draw blood in MAASTRO clinic of all patients with endometrial cancer and store it
encrypted so that we can perform DNA and protein analyses in future and to correlate the
results with survival and toxicity of the treatment.